Jazz Pharmaceuticals plc

NASDAQ:JAZZ  
127.75
+1.62 (+1.28%)
6:03:10 PM EDT: $128.20 +0.45 (+0.35%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)7.85B
Current PEN/A
Forward PE 24.1
2yr Forward PE 5.94
See more stats
Estimates Current Quarter
Revenue$1.11 Billion
Adjusted EPS$5.96
See more estimates
10-Day MA$123.12
50-Day MA$114.44
200-Day MA$119.20
See more pivots

Jazz Pharmaceuticals plc Stock, NASDAQ:JAZZ

Waterloo Exchange, Waterloo Road, Dublin, Dublin 4
Ireland
Phone: +353.1.634.7800
Number of Employees: 2800
http://www.jazzpharmaceuticals.com

Description

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.